These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23839755)

  • 21. Regulation of clinical laboratory information systems after the 1990 amendments to the Food and Drug Act.
    Brannigan VM
    Clin Lab Manage Rev; 1992; 6(1):49-50, 52, 54-7. PubMed ID: 10116934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA increases focus on postmarketing studies.
    Goozner M
    J Natl Cancer Inst; 2010 Sep; 102(17):1302-4. PubMed ID: 20739650
    [No Abstract]   [Full Text] [Related]  

  • 24. The International Consortium of Orthopaedic Registries: overview and summary.
    Sedrakyan A; Paxton EW; Phillips C; Namba R; Funahashi T; Barber T; Sculco T; Padgett D; Wright T; Marinac-Dabic D
    J Bone Joint Surg Am; 2011 Dec; 93 Suppl 3():1-12. PubMed ID: 22262417
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA modernization act of 1997: guidance on medical device tracking; availability--FDA. Notice.
    Fed Regist; 1998 Mar; 63(42):10640-1. PubMed ID: 10177505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to act on drug safety.
    Moore TJ; Psaty BM; Furberg CD
    JAMA; 1998 May; 279(19):1571-3. PubMed ID: 9605903
    [No Abstract]   [Full Text] [Related]  

  • 27. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 28. Ensuring safe and effective medical devices.
    Feigal DW; Gardner SN; McClellan M
    N Engl J Med; 2003 Jan; 348(3):191-2. PubMed ID: 12529457
    [No Abstract]   [Full Text] [Related]  

  • 29. Lessons learned from the COX-2 advisory hearings.
    Somberg J
    Am J Ther; 2005; 12(2):105. PubMed ID: 15767826
    [No Abstract]   [Full Text] [Related]  

  • 30. Dermatology-related postmarketing study commitments to the Food and Drug Administration.
    Bognet RA; Chiang DS; Katz KA
    J Am Acad Dermatol; 2006 Oct; 55(4):721-3. PubMed ID: 17010760
    [No Abstract]   [Full Text] [Related]  

  • 31. The Safe Medical Devices Act: gauging impact on hospitals.
    DePorter J
    Trustee; 1992 Dec; 45(12):19-20. PubMed ID: 10122636
    [No Abstract]   [Full Text] [Related]  

  • 32. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA seeks advice on track-and-trace systems.
    Traynor K
    Am J Health Syst Pharm; 2011 Apr; 68(7):552-4. PubMed ID: 21411794
    [No Abstract]   [Full Text] [Related]  

  • 34. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Device user regulations, not user friendly.
    Cooney J
    AOHA; 1991 Jun; 35(6):4. PubMed ID: 10116065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
    Wallach JD; Ramachandran R; Bruckner T; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postmarketing surveillance--lack of vigilance, lack of trust.
    Fontanarosa PB; Rennie D; DeAngelis CD
    JAMA; 2004 Dec; 292(21):2647-50. PubMed ID: 15572723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.